Statement: the primary trial uses a 3 week cycle for SB-715992 administration, and the study lasts for 21 cycles.
Primary_evidence: INTERVENTION 1:    SB-715992   The eligible participants were administered Ispinesib, intravenously as a one-hour infusion on Day 1 of every 21-day treatment cycle, at a dose of 18 mg/m^2. The dosing was repeated for up to multiple cycles, until disease progression or removal from treatment due to an unacceptable toxicity or withdrawal of consent.